Dual pan-Raf inhibitors, CCT196969 and CCT241161, that also target SRC (SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase) as one of major MAPKs regulatory protein tyrosine kinases, inhibited the growth of NRAS-mutant melanoma cells and achieved tumor regression in patient-derived xenografts that are resistant to B-Raf inhibitors. Here, BRAF is linked to neoplasm.